MCID: MSC072
MIFTS: 47

Muscle Cancer

Categories: Cancer diseases, Muscle diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Muscle Cancer

MalaCards integrated aliases for Muscle Cancer:

Name: Muscle Cancer 11 53 14 16 75
Myosarcoma 11 53 43 71
Malignant Neoplasm of Muscle 11 71
Malignant Tumor of the Muscle 11
Malignant Tumor of Muscle 11
Myomatous Neoplasm 71
Muscle Neoplasms 43

Classifications:



External Ids:

Disease Ontology 11 DOID:4045
NCIt 49 C4883
SNOMED-CT 68 20667008 93913006
ICD10 31 C49
UMLS 71 C0027095 C0282606 C0684743

Summaries for Muscle Cancer

Disease Ontology: 11 A musculoskeletal system cancer that is located in muscle.

MalaCards based summary: Muscle Cancer, also known as myosarcoma, is related to myoma and leiomyosarcoma, and has symptoms including muscle weakness, myoclonus and myalgia. An important gene associated with Muscle Cancer is PAX3 (Paired Box 3), and among its related pathways/superpathways are C-MYB transcription factor network and Regulation of nuclear SMAD2/3 signaling. The drugs Cisplatin and Pembrolizumab have been mentioned in the context of this disorder. Affiliated tissues include muscle, bone and skeletal muscle, and related phenotypes are neoplasm and normal

Wikipedia: 75 A soft-tissue sarcoma (STS) is a malignant tumour, a type of cancer, that develops in soft tissue. A... more...

Related Diseases for Muscle Cancer

Diseases related to Muscle Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 454)
# Related Disease Score Top Affiliating Genes
1 myoma 32.5 TP53 KIT CD34 CALD1
2 leiomyosarcoma 31.9 TP53 SERPINA3 MYOG KIT DES
3 rhabdomyosarcoma 31.8 TP53 PAX7 PAX3 MYOG MYOD1 KIT
4 skeletal muscle cancer 31.7 TP53 TFE3 SERPINA3 RHD PAX7 PAX3
5 leiomyoma 31.2 TP53 KIT DES CD34
6 cutaneous leiomyosarcoma 30.8 KIT CD34 CALD1
7 smooth muscle tumor 30.6 SERPINA3 KIT DES CD34 CALD1
8 botryoid rhabdomyosarcoma 30.6 PAX3 MYOG MYOD1
9 lymphoma, non-hodgkin, familial 30.6 TP53 SERPINA3 MIR9-1 MIR199A1 H2AC18 CD34
10 uterus leiomyosarcoma 30.6 KIT DES
11 bizarre leiomyoma 30.6 TP53 KIT CALD1
12 fibrosarcoma 30.6 TP53 KIT EWSR1 DES
13 infantile myofibromatosis 30.6 MYOG DES CD34 CALD1
14 skin carcinoma 30.5 TP53 MIR199A1 KIT H2AC18
15 intravenous leiomyomatosis 30.5 CD34 CALD1
16 heart cancer 30.5 SERPINA3 MYOG KIT CD34 CALD1
17 hemangiopericytoma, malignant 30.5 SERPINA3 KIT DES CD34 CALD1
18 sarcoma 30.5 TP53 TFE3 SERPINA3 MYOG MYOD1 KIT
19 bladder leiomyoma 30.4 KIT EWSR1 CALD1
20 vulvar leiomyoma 30.3 KIT CD34 CALD1
21 malignant peripheral nerve sheath tumor 30.3 TP53 MYOG KIT CD34
22 angiomyolipoma 30.3 TP53 TFE3 KIT DES
23 neurilemmoma 30.3 SERPINA3 KIT DES CD34 CALD1
24 carcinosarcoma 30.3 TP53 KIT DES
25 spindle cell sarcoma 30.3 TP53 SERPINA3 PAX3 MYOG MYOD1 KIT
26 desmoid tumor 30.3 TP53 KIT DES CD34 CALD1
27 perivascular epithelioid cell tumor 30.2 TFE3 KIT CD34 CALD1 ASPSCR1
28 endometrial stromal sarcoma 30.1 TP53 MYOG KIT H2AC18 EWSR1 DES
29 embryonal rhabdomyosarcoma 30.1 TP53 SERPINA3 RHD PAX7 PAX3 MYOG
30 gastrointestinal stromal tumor 30.1 TP53 SERPINA3 MIR199A1 KIT H2AC18 EWSR1
31 mesenchymal cell neoplasm 30.0 TP53 TFE3 SERPINA3 MYOG MIR199A1 KIT
32 striated muscle rhabdoid tumor 10.8
33 bladder sarcoma 10.6 SERPINA3 MYOG
34 oral rhabdomyosarcoma 10.5 PAX3 MYOG MYOD1
35 central nervous system rhabdomyosarcoma 10.5 PAX3 FOXO1
36 fibroma 10.5 SERPINA3 DES CD34
37 skeletal muscle neoplasm 10.5 RHD MYOG MYOD1
38 gallbladder sarcoma 10.5 MYOG MYOD1 KIT
39 pineal region teratoma 10.5 MYOG MYOD1 KIT
40 conventional leiomyosarcoma 10.5 PAX7 MYOG CALD1
41 vagina leiomyosarcoma 10.5 MYOG KIT CALD1
42 urethra leiomyoma 10.5 KIT CALD1
43 extraosseous ewing sarcoma 10.5 MYOG MYOD1 EWSR1
44 parietal lobe neoplasm 10.5 MYOG MYOD1 CD34
45 orbit embryonal rhabdomyosarcoma 10.5 PAX7 PAX3 MYOG FOXO1
46 blastoma 10.5 TP53 MYOG KIT
47 myofibroma 10.5 MYOG CD34 CALD1
48 gallbladder leiomyoma 10.5 KIT CD34
49 intravascular angioleiomyoma 10.5 CD34 CALD1
50 ureter leiomyoma 10.5 KIT CALD1

Graphical network of the top 20 diseases related to Muscle Cancer:



Diseases related to Muscle Cancer

Symptoms & Phenotypes for Muscle Cancer

UMLS symptoms related to Muscle Cancer:


muscle weakness; myoclonus; myalgia; torticollis; muscle cramp; muscle rigidity; muscle spasticity

MGI Mouse Phenotypes related to Muscle Cancer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.92 CD34 EWSR1 FOXO1 KIT MYOD1 PAX3
2 normal MP:0002873 9.91 EWSR1 FOXO1 KIT MYOD1 MYOG PAX3
3 no phenotypic analysis MP:0003012 9.81 FOXO1 KIT MIR199A1 MIR9-1 MYOD1 MYOG
4 muscle MP:0005369 9.65 CALD1 DES EWSR1 FOXO1 KIT MYOD1
5 integument MP:0010771 9.36 CD34 EWSR1 FOXO1 KIT MIR378A MYOG

Drugs & Therapeutics for Muscle Cancer

Drugs for Muscle Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 14)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
2
Pembrolizumab Approved Phase 3 1374853-91-4 254741536
3
Gemcitabine Approved Phase 3 95058-81-4, 122111-03-9 60750
4 Antiviral Agents Phase 3
5 Anti-Infective Agents Phase 3
6 Antimetabolites Phase 3
7 Antineoplastic Agents, Immunological Phase 3
8 Immunosuppressive Agents Phase 3
9 Immunologic Factors Phase 3
10
Coenzyme M Approved, Investigational Phase 2 3375-50-6 598 23662354
11
Ifosfamide Approved Phase 2 3778-73-2 3690
12
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
13
Palifosfamide Investigational Phase 2 31645-39-3 100427
14 Liposomal doxorubicin Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Randomized Phase 3 Study Evaluating Cystectomy With Perioperative Pembrolizumab and Cystectomy With Perioperative Enfortumab Vedotin and Pembrolizumab Versus Cystectomy Alone in Participants Who Are Cisplatin-Ineligible or Decline Cisplatin With Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303) Recruiting NCT03924895 Phase 3 Pembrolizumab;Enfortumab Vedotin
2 A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy Versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-866) Active, not recruiting NCT03924856 Phase 3 Pembrolizumab;Gemcitabine;Cisplatin;Placebo
3 Hypofractionated 5x5 Gy Radiotherapy With Sequential Doxorubicin and Ifosfamide-based Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Unknown status NCT03651375 Phase 2 Sequential chemotherapy - 3 courses of AI
4 Functional Outcomes and Health Related Quality of Life in Upper-extremity Sarcoma Patients After Limb Salvage: a Prospective Study Completed NCT02380651

Search NIH Clinical Center for Muscle Cancer

Cochrane evidence based reviews: myosarcoma

Genetic Tests for Muscle Cancer

Anatomical Context for Muscle Cancer

Organs/tissues related to Muscle Cancer:

FMA: Muscle
MalaCards : Bone, Skeletal Muscle, Uterus, Smooth Muscle, Small Intestine, Prostate, Trachea

Publications for Muscle Cancer

Articles related to Muscle Cancer:

(show top 50) (show all 142)
# Title Authors PMID Year
1
New genetic tactics to model alveolar rhabdomyosarcoma in the mouse. 53 62
16140913 2005
2
Pseudosarcomatous myofibroblastic tumor and myosarcoma of the urogenital tract. 53 62
11473460 2001
3
Tenosynovial giant cell tumors: evidence for a desmin-positive dendritic cell subpopulation. 53 62
9796719 1998
4
Calpain inhibitors inhibit mitochondrial calpain activity to ameliorate apoptosis of cocultured myoblast. 62
36308077 2022
5
Electroactive functional microenvironments from bioactive polymers: A new strategy to address cancer. 62
35929277 2022
6
The therapeutic potential of RNA Polymerase I transcription inhibitor, CX-5461, in uterine leiomyosarcoma. 62
35201535 2022
7
Oncostatin M Receptor as a Therapeutic Target for Radioimmune Therapy in Synovial Sarcoma. 62
35745569 2022
8
Trismus originating from rare fungal myositis in pterygoid muscles: A case report. 62
34447837 2021
9
Enhancing Peptide Biomaterials for Biofabrication. 62
34451130 2021
10
Cardiac Myosarcoma in a Newborn Infant-A Case Report and Literature Review. 62
34336944 2021
11
From Bench to Bedside in Tongue Muscle Cancer Invasion and Back again: Gross Anatomy, Microanatomy, Surgical Treatments and Basic Research. 62
32932638 2020
12
Opposing effects of 25-hydroxy- and 1α,25-dihydroxy-vitamin D3 on pro-cachectic cytokine-and cancer conditioned medium-induced atrophy in C2C12 myotubes. 62
30834670 2019
13
Diagnostic immunohistochemistry for canine cutaneous round cell tumours - retrospective analysis of 60 cases. 62
31553052 2019
14
Effect of Ninjin'yoeito on the Loss of Skeletal Muscle Function in Cancer-Bearing Mice. 62
30555329 2018
15
Cytotoxicity Studies of the Extracts, Fractions, and Isolated Compound of Pseudocedrela kotschyi on Cervical Cancer (HeLa), Breast Cancer (MCF-7) and Skeletal Muscle Cancer (RD) Cells. 62
28250653 2017
16
Exploration of the anti-enterovirus activity of a series of pleconaril/pirodavir-like compounds. 62
26071135 2015
17
Differential cytotoxic properties of Helleborus niger L. on tumour and immunocompetent cells. 62
25446603 2015
18
Application experience of intraoperative neuromonitoring in thyroidectomy. 62
26885214 2015
19
YAPping about differentiation therapy in muscle cancer. 62
25117705 2014
20
Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma. 62
23665679 2014
21
The not-so-skinny on muscle cancer. 62
23079652 2012
22
Mouse models of sarcomas: critical tools in our understanding of the pathobiology. 62
23036318 2012
23
AKT and PAX3-FKHR cooperation enforces myogenic differentiation blockade in alveolar rhabdomyosarcoma cell. 62
22333587 2012
24
Nephroblastoma overexpressed (NOV/CCN3) gene: a paired-domain-specific PAX3-FKHR transcription target that promotes survival and motility in alveolar rhabdomyosarcoma cells. 62
21423212 2011
25
Histone methyltransferase KMT1A restrains entry of alveolar rhabdomyosarcoma cells into a myogenic differentiated state. 62
21493592 2011
26
Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma. 62
21447712 2011
27
Chandipura virus growth kinetics in vertebrate cell lines, insect cell lines & embryonated eggs. 62
20716815 2010
28
Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia. 62
20193046 2010
29
A novel POK family transcription factor, ZBTB5, represses transcription of p21CIP1 gene. 62
19491398 2009
30
Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma. 62
19339268 2009
31
MyoD and E-protein heterodimers switch rhabdomyosarcoma cells from an arrested myoblast phase to a differentiated state. 62
19299559 2009
32
Correction of dystrophia myotonica type 1 pre-mRNA transcripts by artificial trans-splicing. 62
18923454 2009
33
PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. 62
18679424 2008
34
[Non-epithelial tumors of the large intestine]. 62
19172837 2008
35
A new model for muscle cancer. 62
17585343 2007
36
Identification of a new class of PAX3-FKHR target promoters: a role of the Pax3 paired box DNA binding domain. 62
16964289 2007
37
The homeoprotein six1 transcriptionally activates multiple protumorigenic genes but requires ezrin to promote metastasis. 62
16488997 2006
38
Malignancy-induced autoimmunity to MUC1: initial antibody characterization. 62
16316451 2005
39
Radiation-induced sarcomas after radiotherapy for breast carcinoma: a large-scale single-institution review. 62
15981282 2005
40
Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. 62
15489287 2004
41
New chromanone acids with antibacterial activity from Calophyllum brasiliense. 62
15104480 2004
42
Cytotoxic effects of some animal and vegetable extracts and some chemicals on liver and colon carcinoma and myosarcoma. 62
14968209 2004
43
Synergistic effects of adenosine A1 and P2Y receptor stimulation on calcium mobilization and PKC translocation in DDT1 MF-2 cells. 62
12825834 2003
44
In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A. 62
12447687 2002
45
Prognostic factors and survival in late adolescent and adult patients with small round cell tumors. 62
12151977 2002
46
Successful resection of a re-occurred pulmonary myosarcoma in a patient with turner syndrome mosaic. 62
18521351 2002
47
Modification of hemostatic status improves antitumor efficiency of photodynamic therapy. 62
11427917 2001
48
[Primitive leiomyosarcoma of the right atrium presenting with a pulmonary embolism]. 62
10830098 2000
49
Aggressive congenital fibromatosis of the small intestine in the newborn. Report of a case and review of the literature. 62
10661858 1999
50
Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology. 62
9615866 1998

Variations for Muscle Cancer

Cosmic variations for Muscle Cancer:

8
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM95516578 H3-3A soft tissue,bone,sarcoma,NS c.103G>T p.G35W 1:226064454-226064454 3
2 COSM95520543 H3-3A soft tissue,bone,sarcoma,NS c.103G>T p.G35W 1:226064454-226064454 3
3 COSM95523461 H3-3A soft tissue,bone,sarcoma,NS c.103G>T p.G35W 1:226064454-226064454 3
4 COSM95526780 H3-3A soft tissue,bone,sarcoma,NS c.103G>T p.G35W 1:226064454-226064454 3
5 COSM87494413 GNAQ soft tissue,bone,sarcoma,NS c.442C>T p.R148* 9:77815650-77815650 3

Expression for Muscle Cancer

Search GEO for disease gene expression data for Muscle Cancer.

Pathways for Muscle Cancer

GO Terms for Muscle Cancer

Biological processes related to Muscle Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of DNA-templated transcription GO:0006355 10.02 TP53 TFE3 PAX7 PAX3 MYOG MYOD1
2 muscle cell fate commitment GO:0042693 9.56 MYOG MYOD1
3 positive regulation of myoblast differentiation GO:0045663 9.55 MYOG MYOD1 MIR199A1
4 muscle organ development GO:0007517 9.5 PAX7 PAX3 MYOG MYOD1
5 anatomical structure development GO:0048856 9.1 PAX7 PAX3 MYOG MYOD1

Molecular functions related to Muscle Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity GO:0003700 9.44 TP53 TFE3 PAX7 PAX3 MYOG MYOD1
2 mRNA base-pairing translational repressor activity GO:1903231 9.26 MIR9-1 MIR675 MIR378A MIR199A1

Sources for Muscle Cancer

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....